Lower level of circulating myostatin was recently reported in serum from untreated SMA patients and individuals with other dystrophic conditions.25 This may explain for the unsatisfactory clinical efficacy of anti‐myostatin approaches in a number of clinical trials for muscular dystrophies. The gene discussed is MSTN; the disease is muscular dystrophy.